{"filing":{"accession_number":"0001193125-26-298979","cik":"0001994702","ticker":"KYTX","company_name":"Kyverna Therapeutics, Inc.","form":"8-K","filing_date":"2026-07-09","report_date":null,"primary_document":"kytx-20260708.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1994702/000119312526298979/kytx-20260708.htm"},"events":[{"id":17210,"run_id":15396,"accession_number":"0001193125-26-298979","anchor_item_number":"1.01","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"The filing discloses entry into a material definitive agreement—an amendment to an existing Loan and Security Agreement with Oxford Finance LLC that modifies the terms and availability of a $150 million non-dilutive term loan facility. The amendment extends the availability of the remaining $15 million of Term A Loans through December 31, 2026, and conditionally extends the availability of Term B and Term C Loans, along with modifications to revenue covenants and non-utilization fees. This is a material modification to the Company's direct financial obligations and capital structure.","company_name":"Kyverna Therapeutics, Inc.","ticker":"KYTX","filing_date":"2026-07-09","form":"8-K","submitted_at":null,"items":[{"id":15579,"accession_number":"0001193125-26-298979","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The filing discloses entry into a material definitive agreement—an amendment to an existing Loan and Security Agreement with Oxford Finance LLC that modifies the terms and availability of a $150 million non-dilutive term loan facility. The amendment extends the availability of the remaining $15 million of Term A Loans through December 31, 2026, and conditionally extends the availability of Term B and Term C Loans, along with modifications to revenue covenants and non-utilization fees. This is a material modification to the Company's direct financial obligations and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T13:04:41.883814+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":15579,"accession_number":"0001193125-26-298979","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The filing discloses entry into a material definitive agreement—an amendment to an existing Loan and Security Agreement with Oxford Finance LLC that modifies the terms and availability of a $150 million non-dilutive term loan facility. The amendment extends the availability of the remaining $15 million of Term A Loans through December 31, 2026, and conditionally extends the availability of Term B and Term C Loans, along with modifications to revenue covenants and non-utilization fees. This is a material modification to the Company's direct financial obligations and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T13:04:41.883814+00:00","company_name":"Kyverna Therapeutics, Inc.","ticker":"KYTX","filing_date":"2026-07-09"}]}